Curasight

"Looking back on 2024, the year was a busy year for Curasight where we made progress in our clinical development activities against a backdrop of a very challenging macroeconomic climate. We intensified our business development activities, pursuing discussions with key industry players on potential strategic partnerships, and look forward to continuing these efforts in 2025. This has resulted in a strengthening of our strategic investor base, as Curium and Pentwater will become shareholders in Curasight in connection with the annonced capital raising in the first half of 2025. We also continued activities to deliver on our strategy to accelerate clinical development of uTREAT®, where we have chosen brain cancer as the indication for the initial clinical trial. This is in line with our aim to build on Curasight's theranostic approach, developing both diagnostic (uTRACE) and treatment (uTREAT) options in parallel." Commented Commented Curasight's CEO Ulrich Krasilnikoff. "We look forward to continuing momentum in 2025, in particular with our clinical development in parallel of both our diagnostic (uTRACE) by conducting the phase IIa study in prostate cancer partnered with Curium and our therapeutic (uTREAT) in brain cancer funded in part by the proceeds from the rights issue that we recently launched."

Financial Highlights January - December 2024

• Gross loss amounted to kDKK -32,731 (kDKK -25,729)
• Operating loss amounted to kDKK -40,367 (kDKK -33,214)
• Loss before tax amounted to kDKK -42,336 (kDKK -33,220)
• Loss for the year amounted to kDKK -36,836 (kDKK -26,169)
• Total assets amounted to kDKK 23,688 (kDKK 38,742)
• Equity ratio amounted to 32.6% (81.0%)
• Earnings per share amounted to DKK -1,74 (DKK -1,32)

Numbers in parenthesis are numbers from the same period in 2023.

Business Highlights from 2024

On January 22, Curasight announced the achievement of the first milestone under the agreement with Curium inc., to develop Curasight's uTRACE® PET imaging technology for the improved diagnosis of prostate cancer. The milestone relates to the validation of GMP manufacturing of the finished product.

On April 16, Curasight announced the approval of a clinical trial application (CTA) from the European Medicines Agency (EMA) for the investigation of uTRACE® in a phase 2 trial as a non-invasive alternative or supplement to traditional biopsies in prostate cancer patients in active surveillance.

On June 12, Curasight announced the enrolment of the first patient in the Phase 2 trial using uTRACE PET imaging technology for the improved diagnosis in prostate cancer. The news triggers the second USD 500.000 milestone under the agreement with Curium Inc., signed in May 2023.

On June 14, Curasight' BoD resolved to execute directed issues of shares of a total of approximately DKK 7.8 million. Curasight has also secured a loan facility of in total DKK 20 million from Fenja and from the loan facility the Company has decided to immediately draw a tranche of DKK 10 million.

On July 2, Curasight held an Extraordinary General Meeting to resolve the authorization of the BoD to issue warrants. The Minutes with summarised decisions are available on Curasight's website.

On September 4, Curasight announced that the Board of Directors had resolved on a directed issue of units (warrants of series TO2 and series TO3) to the shareholders in the Company.

On October 3, Curasight announced that the rights issue was heavily oversubscribed

On November 11, announced brain cancer (high-grade glioma (HGG)) as the first indication for uTREAT as a potential cancer therapeutic.

On November 13, publication of the international patent application for uTREAT. The patent application is in addition to already granted patents covering the company's peptide-based uPAR-targeting technology and if granted will extend patent protection to 2043.

On November 22, announced that the Company has entered into a clinical supply agreement with Curium - a global leader in radiopharmaceuticals - for the supply of non-carrier-added Lutetium-177 for Curasight's uTREAT.